TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06412471
Drug: PD-1/L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors
Study: NCT06596915
Drug: BA1302
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA1302 administered intravenously
Study: NCT06594822
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily
Study: NCT06589219
Drug: CMR316
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort
Study: NCT05637086
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
Study: NCT05637086
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
Study: NCT06589219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration
Study: NCT06590714
Drug: Experimental(Acelex cap m2mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Arm (Polmacoxib (Acelex cap 2mg + NSAIDs-excluded non-opioid or opioid analgesics))~Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.~NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
Study: NCT05615948
Drug: VTS-K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary oral formulation of 486mg aspirin and 80mg ketamine
Study: NCT06602557
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients included in the inhaled amikacin group will receive inhaled antibiotic therapy by nebulization of amikacin at a dose of 25 mg/kg in 1 daily dose (+/- 3 hours apart), within 6 hours of randomization and for a total duration of 5 days.
Study: NCT06602557
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the standard of care group will not receive any nebulization. They will receive Standard care alone.
Study: NCT06594315
Drug: Deuterated Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT06601283
Drug: Vitmain C plus herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
Study: NCT06591494
Drug: Classic quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID
Study: NCT06591494
Drug: Quadruple therapy with sodium bicarbonate instead of clarithromycin
Normalized name: Neut brand of sodium bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Sodium bicarbonate 500 mg TID
Study: NCT05611281
Drug: GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage was calculated according to body weight and dose group once a day according to the assigned group.
Study: NCT06537414
Drug: Bepirovirsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen will be administered
Study: NCT06537414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT04984668
Drug: GT90001+KN046
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT90001 7.0mg/Kg， KN046 5mg/Kg
Study: NCT04984668
Drug: GT90001+KN046
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT90001 7.0mg/Kg ， KN046 3mg/Kg
Study: NCT04984668
Drug: GT90001/KN046
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT90001 4.5mg/Kg / KN046 5mg/Kg
Study: NCT04984668
Drug: GT90001+KN046
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT90001 4.5mg/Kg， KN046 3mg/Kg
Study: NCT04984668
Drug: GT90001+KN046
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT90001 3mg/Kg ， KN046 3mg/Kg
Study: NCT06603363
Drug: Rosuvastatin 40mg
Normalized name: ROSUVASTATIN 40MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 40 mg of rosuvastatin once a day for 3 months. After the 3-month visit, the dose will be reduced to a dose per standard of care.
Study: NCT06603363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo for rosuvastatin once a day for 3 months. After the 3-month visit, standard rosuvastatin will be initiated.
Study: NCT05605522
Drug: [225]-FPI-2059
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.~In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation.
Study: NCT05605522
Drug: [111In]-FPI-2058
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.
Study: NCT00000827
Drug: Anti-HIV Immune Serum Globulin (Human)
Normalized name: immune globulin subcutaneous (human)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05345639
Drug: LRA Loco-regional anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, at the end of surgery in the operating room. Once in the desired plane depending on the randomisation (transverse or parasternal), a volume of 20 ml of ropivacaine at 2 mg/ml is injected on each side of the sternum.~The intervention (TTP or PSB) is performed by the anesthetist-resuscitator investigator.
Study: NCT04853069
Drug: Transdermal estradiol gel
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
Study: NCT05239390
Drug: SCI -110
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis.
Study: NCT06313567
Drug: Metronomic capecitabine group
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
Study: NCT06128954
Drug: 900mg TETA 4HCl Once Daily Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x300mg trientine base tablets as a single AM dose
Study: NCT06128954
Drug: 900mg TETA 4HCl Cuprior®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 x150mg trientine base tablets in two equally divided doses
Study: NCT05233956
Drug: COCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
Study: NCT05360004
Drug: Chinese herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
Study: NCT06025773
Drug: Lansoprazole 15mg/Calcium carbonate 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
Study: NCT05679401
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
Study: NCT05679401
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids inhibit the inflammation process.
Study: NCT04830813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
Study: NCT04639245
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05852574
Drug: CP-101 + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo in this trial will be presented in capsules that are identical in size, smell, texture, and appearance to those of the CP101 capsules. These will be produced by the BWH investigational drug service
Study: NCT05386368
Drug: ReCell
Normalized name: QUEEN PURECELL WHITENING 3-STEP MASK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform).
Study: NCT05939882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drop
Study: NCT06088017
Drug: CKD-331, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04849247
Drug: 68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
Study: NCT06297369
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
Study: NCT04370301
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04370301
Drug: JAK Inhibitor
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05479877
Drug: sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
Study: NCT04234477
Drug: Calcium channel blocker strategy
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
Study: NCT04234477
Drug: Physician preference strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil.
Study: NCT05097079
Drug: MYOBLOC Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to the MYOBLOC Low Dose treatment group will be administered MYOBLOC (60 units/kg; maximum 1800 units) as a single treatment via intraglandular injection (5.0 units/kit per submandibular gland \[maximum 150 units\] and 25.0 units/kg per parotid gland \[maximum 750 units\])
Study: NCT05097079
Drug: MYOBLOC High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to the MYOBLOC High Dose treatment group will be administered MYOBLOC (100 units/kg; maximum 3000 units) as a single treatment via intraglandular injection (25.0 units/kit per submandibular gland \[maximum 300 units\] and 40.0 units/kg per parotid gland \[maximum 1200 units\])
Study: NCT05097079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to the Placebo treatment group will be administered volume-matched placebo (1:1)
Study: NCT06450899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo arm individuals will receive a non-identical inert generic placebo tablet containing microcrystalline cellulose provided by Belmar Pharma Solutions. Placebo tablets will be taken at the same time and frequency as the study intervention drug.
Study: NCT06039579
Drug: VH4004280
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4004280 will be administered.
Study: NCT06039579
Drug: VH4011499
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4011499 will be administered.
Study: NCT06039579
Drug: VH4004280 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4004280 matching placebo will be administered.
Study: NCT06039579
Drug: VH4011499 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4011499 matching placebo will be administered.
Study: NCT05604859
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
Study: NCT05017116
Drug: RBD1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT05017116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT03708926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection pen
Study: NCT04251715
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06065371
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
Study: NCT04984616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Placebo daily for 120 days
Study: NCT05515887
Drug: Shenqu Xiaoshi Oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage was determined by age: 3-4 years old, 5 ml/dose; 5-14 years old 10 ml/dose. Taken half an hour after meals, three times a day.
Study: NCT06540261
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04944966
Drug: Maytenus Senegalensis
Normalized name: Khaya senegalensis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg
Study: NCT04971746
Drug: GLPG4716
Approvals — FDA: no, EMA: no, PMDA: no
Description: From Day 3 to Day 14, participants will receive GLPG4716 daily.
Study: NCT05636228
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution
Study: NCT05082610
Drug: HMBD-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.
Study: NCT05090111
Drug: ALG-055009
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of ALG-055009
Study: NCT04181359
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Study: NCT04181359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study: NCT05846659
Drug: IMSA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
Study: NCT05718024
Drug: Propofol-remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
Study: NCT05283161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
Study: NCT05443802
Drug: Insulin 0.05 IU/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
Study: NCT05443802
Drug: Insulin 0.10 IU/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
Study: NCT06601036
Drug: 2% Xylocaine (2 ml )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo fiberoptic intubation with bilateral Superior Laryngeal Nerve block and Recurrent laryngeal nerve block.
Study: NCT06588699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo taken orally once daily
Study: NCT06281236
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
Study: NCT06281236
Drug: SPI-62
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI-62 administered once daily.
Study: NCT06515834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
Study: NCT05024721
Drug: HIP2101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT05602818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06603142
Drug: AR882 25MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 25 MG Capsules
Study: NCT06603142
Drug: AR882 12.5MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 12.5 MG Capsules
Study: NCT06603142
Drug: AR882 25MG Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 25MG Placebo
Study: NCT06603142
Drug: AR882 12.5MG Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 12.5MG Placebo
Study: NCT06599151
Drug: [18F]FTC-146
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
Study: NCT05006352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT06586294
Drug: Drug: AK129 Drug：oxaliplatin Drug：capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK129 is administered intravenously according to the frequency every three weeks(Q3W) and different dosage of administration at different stages.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
Study: NCT06586294
Drug: Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK129 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages. Cadonilimab is administered intravenously according to the frequency and dosage 10mg/kg Q3W.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
Study: NCT06590662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period.~Placebo will be taken once a day upon awakening Schema of dispensation~1. One tablet of placebo per day for 1 week (week 1)~2. Two tablets of placebo per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Either maintained stable with 2 tablets or increased to 4 tablets per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 2 or 4 tablets or reduced at 2 tablets per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks placebo period.